Outset Medical Inc. (OM)
OM trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1484612/000119312526051278/0001193125-26-051278-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | OM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001484612 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $119.5M |
| Net income | -$81.7M |
| Operating income | -$66.7M |
| Net margin | -68.3% |
| Operating margin | -55.8% |
| Revenue growth | +5.1% |
| Cash | $35.0M |
| Total assets | $264.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $33.9M cash; operating cash flow -$10.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 18,872,597 (2026-11-02); 18,153,090 a year earlier; 50,204,570 three years earlier. 3y figure adjusted for split (1-for-15 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-15 on 2025-03-20 | Source 2025-03-20 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $369K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $33.6M | -$14.7M | -$10.4M | $33.9M | $98.4M | $122.0M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $31.6M | -$18.0M | -$9.6M | $35.0M | $97.6M | $117.8M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $27.9M | -$19.0M | -$12.8M | $30.6M | $96.9M | $117.6M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $28.9M | -$19.5M | -$9.5M | $35.0M | $96.2M | $119.5M | 10-K 2026-02-13 |
| Q3 2025 2025-09-30 | $29.4M | -$17.8M | -$6.3M | $36.4M | $95.5M | $120.1M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $31.4M | -$18.5M | -$4.8M | $39.6M | $94.8M | $119.3M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $29.8M | -$25.8M | -$25.7M | $75.9M | $94.1M | $115.3M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $29.5M | -$25.6M | -$16.5M | $124.0M | $197.4M | $113.7M | 10-K 2026-02-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-02-28 |
| Latest annual report | 10-K | 2026-02-13 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 746 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.8% |
| 1 month | -8.1% |
| 3 months | -12.2% |
| Year to date | +0.5% |
| 1 year | -23.9% |
| From 52-week high | -34.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HYPR | Hyperfine Inc. | $0.6101 | -3.05% | $64.8M |
| NRXS | Neuraxis Inc. | $4.80 | -11.44% | $68.1M |
| POCI | Precision Optics Corporation Inc. | $4.97 | -4.97% | $54.6M |
| STXS | Stereotaxis Inc. | $0.8027 | -4.80% | $80.4M |
| ECOR | electroCore Inc. | $4.84 | -7.81% | $44.7M |
| VANI | Vivani Medical Inc. Common Stock (DE) | $1.02 | +0.99% | $92.0M |
| HSDT | Solana Company Class A Common Stock (DE) | $1.64 | -5.20% | $103.1M |
| FOCL | EDAP TMS S.A. | $3.17 | -2.39% | $149.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier